Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

Ines Pires da Silva; Danny Zakria; Tasnia Ahmed; Claudia Trojanello; Florentia Dimitriou; Clara Allayous; Camille Gerard; Lisa Zimmer; Serigne Lo; Olivier Michielin; Celeste Lebbe; Johanna Mangana; Paolo Antonio Ascierto; Douglas B Johnson; Matteo Carlino; Alexander Menzies; Georgina Long

doi:10.1136/jitc-2022-004610

Article info

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

Authors

Ines Pires da Silva Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, AustraliaBlacktown & Westmead Hospital, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Danny Zakria Vanderbilt University Medical Center, Nashville, Tennessee, USA PubMed articles Google scholar articles
Tasnia Ahmed Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia PubMed articles Google scholar articles
Claudia Trojanello Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy PubMed articles Google scholar articles
Florentia Dimitriou Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland PubMed articles Google scholar articles
Clara Allayous Dermatolo-Oncology AP-HP Hôpital Saint-Louis, INSERM U976, Paris, France PubMed articles Google scholar articles
Camille Gerard Precision Oncology Centre, CHUV, Lausanne, Switzerland PubMed articles Google scholar articles
Lisa Zimmer Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany PubMed articles Google scholar articles
Serigne Lo Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia PubMed articles Google scholar articles
Olivier Michielin Precision Oncology Centre, CHUV, Lausanne, Switzerland PubMed articles Google scholar articles
Celeste Lebbe Université Paris Cite, Dermatolo-Oncology AP-HP Hôpital Saint-Louis, INSERM U976, Paris, France PubMed articles Google scholar articles
Johanna Mangana Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland PubMed articles Google scholar articles
Paolo Antonio Ascierto Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy PubMed articles Google scholar articles
Douglas B Johnson Vanderbilt University Medical Center, Nashville, Tennessee, USA PubMed articles Google scholar articles
Matteo Carlino Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, AustraliaBlacktown & Westmead Hospital, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Alexander Menzies Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, AustraliaRoyal North Shore and Mater Hospitals, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Georgina Long Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, AustraliaFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, AustraliaRoyal North Shore and Mater Hospitals, Sydney, New South Wales, Australia PubMed articles Google scholar articles

Citation

Pires da Silva I, Zakria D, Ahmed T, et al

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

Journal for ImmunoTherapy of Cancer 2022;10:e004610. doi: 10.1136/jitc-2022-004610

Online issue publication

October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password